Pharmaceutical combination and use thereof
US-2024189341-A1 · Jun 13, 2024 · US
Mucosal vaccines with chitosan adjuvant and meningococcal antigens
US8926992B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8926992-B2 |
| Application number | US-51420703-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 14, 2003 |
| Priority date | May 14, 2002 |
| Publication date | Jan 6, 2015 |
| Grant date | Jan 6, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis , and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis . It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.
First claim
Opening claim text (preview).
The invention claimed is: 1. An immunogenic composition, comprising (a) a capsular saccharide antigen from serogroup C of N.meningitidis , (b) a chitosan adjuvant, and (c) a detoxified mutant of E. coli heat-labile toxin. 2. An immunogenic composition for mucosal delivery, comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N.meningitidis , a chitosan adjuvant, and a detoxified mutant of E.coli heat-labile toxin.…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K39/095Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8926992B2 cover?
- The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis , and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides …
- Who is the assignee on this patent?
- Del Guidice Giuseppe, Baudner Barbara, Novartis Ag, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/095. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).